Science

Leo Mascarenhas: Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas

Leo Mascarenhas/cedars-sinai.org

Jan 29, 2025, 12:53

Leo Mascarenhas: Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas

Leo Mascarenhas, Division Chief and Director of Pediatric Hematology and Oncology at Cedars-Sinai Guerin Children, shared an article on LinkedIn:

“Hot of the press!

Some insight into the implications of stopping treatment in young sarcoma patients!”

Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.

Authors: Leo Mascarenhas, et al.

Leo Mascarenhas: Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas

cancer Cedars-Sinai Guerin Children fight against cancer Global fight against cancer Hematology larotrectinib Leo Mascarenhas Mesenchymal Tumors OncoDaily Oncology

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding